Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EBITDA: 2020-2024

Historic EBITDA for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$42.9 million.

  • SAB Biotherapeutics' EBITDA fell 12.11% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 16.58%. This contributed to the annual value of -$42.9 million for FY2024, which is 12.70% down from last year.
  • Per SAB Biotherapeutics' latest filing, its EBITDA stood at -$42.9 million for FY2024, which was down 12.70% from -$38.1 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year EBITDA high stood at $20.6 million for FY2020, and its period low was -$42.9 million during FY2024.
  • In the last 3 years, SAB Biotherapeutics' EBITDA had a median value of -$38.1 million in 2023 and averaged -$36.6 million.
  • Data for SAB Biotherapeutics' EBITDA shows a maximum YoY plummeted of 165.15% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' EBITDA stood at $20.6 million in 2020, then slumped by 165.15% to -$13.4 million in 2021, then slumped by 115.91% to -$28.9 million in 2022, then crashed by 31.67% to -$38.1 million in 2023, then decreased by 12.70% to -$42.9 million in 2024.